Final Glance: Biotechnology companies
AP - Thu May 15, 5:15PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Midday Glance: Biotechnology companies
AP - Thu May 15, 12:31PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu May 15, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2014
Business Wire - Wed May 14, 4:19PM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced more than 65 abstracts reporting on investigational studies in blood and solid tumor cancers will be presented during the 50th American Society of Clinical Oncology meeting in Chicago, Ill. from May 30 to June 3, 2014.
Critical Alerts For DirecTV, JPMorgan, First Solar, Celgene, and Baidu.com Released By InvestorsObserver
PR Newswire - Wed May 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DTV, JPM, FSLR, CELG, and BIDU.
Clinical Trial Results, Acquisitions, Healthcare Partnership, and Pricing of Senior Notes - Analyst Notes on Merck, JNJ, Chelsea, Unitedhealth and Celgene
PR Newswire - Tue May 13, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Unitedhealth Group, Inc. (NYSE: UNH) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2377-100free.
Celgene Rises 2.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 12, 4:00PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.63% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Will Patterson (PDCO) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 12:00PM CDT
Patterson's (PDCO) bottom-line growth was on par with the Zacks Consensus Estimate.
Celgene Earnings Review: 18 Days after Announcement Shares Up 3.8% (CELG)
Comtex SmarTrend(R) - Mon May 12, 11:09AM CDT
When Celgene (NASDAQ:CELG) reported earnings 18 days ago on April 24th, 2014, analysts, on average, expected the company to report earnings of $1.65 on sales of $1.8 billion. The company actually reported EPS of $1.67 on sales of $1.7 billion, beating EPS estimates by $0.02 and missing revenue estimates by $35.1 million. Shares of Celgene have climbed from $141.25 to $146.67, representing a gain of 3.8% since the company reported earnings 18 days ago.
Here's What These $3 Billion Money Managers Have Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Mon May 12, 10:05AM CDT
Every quarter, many money managers have to disclose what they've bought and sold via "13F" filings. Their latest moves can shine a bright light on smart stock picks. Today, let's look at Todd Asset Management. Based in Kentucky, the money managers'...
Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
How This 1 Company Is Attempting to Overcome One of Cancer's Greatest Risk Factors
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 1:05PM CDT
Cancer is one of the scariest disease diagnoses imaginable, at least according to one U.K. study , and that's primarily because researchers, despite decades of work and collaboration, are still scratching the surface on what triggers cancer in the...